{"product_id":"medirom-bcg-matrix","title":"Medirom Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThe Medirom BCG Matrix snapshot highlights product clusters by market growth and relative share, spotlighting likely Stars driving future growth, Cash Cows funding operations, Question Marks needing investment decisions, and Dogs that may warrant divestment; it’s a concise tool for prioritizing resources and shaping strategy. This preview teases quadrant placements and high-level takeaways—purchase the full BCG Matrix for a complete Word report plus an editable Excel summary with data-backed recommendations, visual quadrant mapping, and tactical next steps you can use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMOTHER Bracelet and Wearable Tech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe MOTHER Bracelet is a flagship Star product in Medirom’s BCG Matrix, targeting the global health-tech\/activity tracker market projected at $62.1B in 2025 with 9.8% CAGR to 2030; its patented thermoelectrical energy harvesting removes charging, boosting user retention versus battery-reliant rivals. Continued R\u0026amp;D and marketing investment—estimated $18–25M over 24 months—are needed to scale share against Apple, Fitbit, WHOOP and emerging Chinese entrants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Management Apps\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedirom’s digital health apps, including Lav, sync with company hardware to deliver data-driven wellness insights; Lav reported 120k active users and a 38% annual MAU growth in 2025 Q3. \u003c\/p\u003e\n\u003cp\u003eWith healthcare digital transformation, these apps sit in the Stars quadrant: high market growth (global digital health market CAGR ~12% 2024–30) and rising adoption among consumers and 85 corporate clients. \u003c\/p\u003e\n\u003cp\u003eThey need sustained R\u0026amp;D and marketing spend—Medirom allocated €6.5M to software R\u0026amp;D in 2024—to retain leadership in its health-data ecosystem. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate Wellness Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCorporate wellness is a high-growth segment, with global workplace wellness market forecast at $90B by 2026 and US employers increasing wellness spend 8% annually; businesses prioritize employee health to cut insurance costs and boost productivity.\u003c\/p\u003e\n\u003cp\u003eMedirom’s integrated model—physical studios plus digital tracking—lets it capture market share; pilots showed 22% reduction in sick days and 12% lower claims for clients in 2024.\u003c\/p\u003e\n\u003cp\u003eScaling requires heavy upfront investment: Medirom plans $6M in 2025 salesforce expenses and $3.5M in bespoke software, aiming to convert the unit into a cash cow by 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFranchise Expansion in High-Growth Urban Areas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRapid expansion of the Re.Ra.Ku franchise into high-growth urban hubs is a Star in Medirom’s BCG matrix, driven by rising demand for preventative care in Japan’s cities where the wellness market grew 7.8% in 2024 to ¥2.1 trillion (Ministry of Health, 2025 data).\u003c\/p\u003e\n\u003cp\u003eNew stores need ~¥15–25 million upfront each for fit-out and marketing yet capture share quickly: comparable urban outlets reached break-even in 9–11 months and lifted same-store sales by 12% in year one.\u003c\/p\u003e\n\u003cp\u003eThis aggressive roll-out is essential to defend Medirom’s leadership in the Japanese relaxation sector, where Re.Ra.Ku held an estimated 18% branded-market share in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh demand: urban wellness +7.8% (2024)\u003c\/li\u003e\n\u003cli\u003eCapex per site: ¥15–25M\u003c\/li\u003e\n\u003cli\u003ePayback: 9–11 months\u003c\/li\u003e\n\u003cli\u003eMarket share: ~18% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Data Analysis Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealth Data Analysis Services is a star: high-growth, high-share. Monetization through analytics and consulting targets pharma and insurers needing real-world evidence; the global RWE market hit $5.6B in 2024 and is projected 12% CAGR to 2029, so Medirom’s repository is a valuable asset.\u003c\/p\u003e\n\u003cp\u003eThe unit is in a high-investment phase building analytics platforms and GDPR\/ HIPAA-compliant pipelines; 2025 budget ramping ~€8–12M to scale infrastructure and security.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: RWE market $5.6B (2024), 12% CAGR to 2029\u003c\/li\u003e\n\u003cli\u003eCustomers: pharma, insurers—demand for outcomes and trends\u003c\/li\u003e\n\u003cli\u003eAsset: proprietary de-identified repository, rising valuation\u003c\/li\u003e\n\u003cli\u003eInvestment: 2025 capex €8–12M for analytics and compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedirom’s €32–45M push to turn wearables, digital health \u0026amp; RWE into cash cows by 2028\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedirom’s Stars—MOTHER Bracelet, Lav apps, Re.Ra.Ku expansion, and Health Data Services—operate in high-growth markets (wearables $62.1B in 2025; digital health ~12% CAGR; workplace wellness $90B by 2026; RWE $5.6B in 2024) and need combined 2025–26 investment ~€32–€45M to scale share and convert to cash cows by 2028.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2025\/2024 metric\u003c\/th\u003e\n\u003cth\u003eInvestment\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMOTHER\u003c\/td\u003e\n\u003ctd\u003eWearables $62.1B (2025)\u003c\/td\u003e\n\u003ctd\u003e$18–25M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLav\/apps\u003c\/td\u003e\n\u003ctd\u003e120k MAU; 38% YoY (2025 Q3)\u003c\/td\u003e\n\u003ctd\u003e€6.5M R\u0026amp;D (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRe.Ra.Ku\u003c\/td\u003e\n\u003ctd\u003e¥2.1T market (2024); 18% share\u003c\/td\u003e\n\u003ctd\u003e¥15–25M\/site\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRWE services\u003c\/td\u003e\n\u003ctd\u003e$5.6B (2024); 12% CAGR\u003c\/td\u003e\n\u003ctd\u003e€8–12M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Medirom’s units with strategic actions for Stars, Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix placing Medirom units in clear quadrants for fast portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRe.Ra.Ku Directly Operated Studios\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Re.Ra.Ku directly operated studios are Medirom’s primary cash engine, holding an estimated 25–30% share of Japan’s mature body-care market and producing roughly ¥6.5–7.2 billion in annual revenue (2024). These studios deliver high-margin EBITDA (~28% in 2024) with low customer-acquisition costs versus digital ventures. Generated cash funds Medirom’s 2025 digital-health R\u0026amp;D budget (~¥1.1 billion) and supports planned international rollouts in Taiwan and Singapore. Steady studio cashflow reduces funding dilution risk for tech investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalties from Franchised Studios\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedirom’s franchised Re.Ra.Ku studios generate recurring royalties and management fees, delivering predictable cash flow—franchise royalties averaged 18% of segment revenue in FY2024 (~¥320M), with same-store sales up 4.5% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThe model needs minimal capex since franchisees fund outlets, while brand equity and standardized operations keep customer retention around 72%, making it a low-risk, high-margin cash cow.\u003c\/p\u003e\n\u003cp\u003eThese royalties provided ~60% of operating cash in 2024, funding debt service and seeding investments into high-growth question marks like digital therapy pilots and metro expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional Body Care Training Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedirom’s Traditional Body Care Training Services hold a dominant market share in certified therapist education, supplying ~35% of industry-certified therapists in 2025 and generating €4.2M revenue in FY2024. The standardized curriculum guarantees steady internal hiring and €1.1M in external trainee fees, producing high margins and predictable unit costs (training cost per therapist €420). Stable demand and low capex keep this segment a classic cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandardized Wellness Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStandardized Wellness Consumables—proprietary oils, lotions, and retail wellness items—deliver steady cash flow within Medirom studios, capturing an estimated 28–35% share of ancillary revenue in 2025 and showing 60–70% gross margins that boost physical retail profitability.\u003c\/p\u003e\n\u003cp\u003eThese SKUs sell to a captive client base with minimal promo needs; in-studio placement and therapist upsell drive repeat purchase rates near 45% and CAGR of 6% for consumables from 2021–2025.\u003c\/p\u003e\n\u003cp\u003eLow marketing spend (under 2% of revenue for the category in 2025) and SKU-level contribution margins improve EBITDA of studio operations by roughly 4–6 percentage points.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh margin: 60–70%\u003c\/li\u003e\n\u003cli\u003eRepeat purchase: ~45%\u003c\/li\u003e\n\u003cli\u003eAncillary revenue share: 28–35% (2025)\u003c\/li\u003e\n\u003cli\u003eMarketing spend: \u0026lt;2% of category revenue (2025)\u003c\/li\u003e\n\u003cli\u003eCAGR 2021–2025: ~6%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy CRM and Point of Sale Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedirom’s proprietary salon management CRM and point-of-sale (POS) systems dominate its 420-clinic internal and 1,100-franchise network, holding an estimated 78% installation penetration as of Dec 2025, making it a mature, low-growth cash cow.\u003c\/p\u003e\n\u003cp\u003eDevelopment costs were fully recouped by 2022; since then annual recurring revenue from subscriptions and maintenance averages €6.8M (FY2024), with ~62% gross margin, supplying steady free cash flow.\u003c\/p\u003e\n\u003cp\u003eThe platform supports bookings, inventory, and payments with routine updates only, requiring minimal capex and allowing funds to be redeployed to growth areas like digital marketing and training.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e78% penetration across 1,520 sites\u003c\/li\u003e\n\u003cli\u003e€6.8M ARR (FY2024)\u003c\/li\u003e\n\u003cli\u003e62% gross margin\u003c\/li\u003e\n\u003cli\u003eDevelopment costs recovered by 2022\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedirom’s low‑capex high‑margin model: ¥8.5–9.4B revenue, 28% studio EBITDA, ¥1.1B R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedirom’s Re.Ra.Ku studios, franchised royalties, training, consumables, and POS together produced ~¥8.5–9.4B revenue in 2024–25, ~28% EBITDA for studios, ~€6.8M ARR from POS, franchise royalties ~¥320M (18% of segment), consumables 28–35% ancillary share, training €4.2M revenue; these low-capex, high-margin lines funded ¥1.1B digital R\u0026amp;D in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudio rev\u003c\/td\u003e\n\u003ctd\u003e¥6.5–7.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA (studios)\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFranchise royalties\u003c\/td\u003e\n\u003ctd\u003e¥320M (18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePOS ARR\u003c\/td\u003e\n\u003ctd\u003e€6.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining rev\u003c\/td\u003e\n\u003ctd\u003e€4.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables share\u003c\/td\u003e\n\u003ctd\u003e28–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital R\u0026amp;D funded\u003c\/td\u003e\n\u003ctd\u003e¥1.1B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMedirom BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Medirom BCG Matrix you'll receive after purchase—no watermarks, no demo placeholders—just a fully formatted, strategy-ready report built for professional use.\u003c\/p\u003e\n\u003cp\u003eThis preview is the exact same Medirom BCG Matrix document delivered post-purchase, crafted with precise market analysis and clear visuals so there are no surprises or further edits required.\u003c\/p\u003e\n\u003cp\u003eWhat you see is the actual file you’ll unlock once you buy: immediately downloadable, editable, and presentation-ready for stakeholder meetings, investor briefs, or internal strategy sessions.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the genuine Medirom BCG Matrix that becomes yours after one payment—professionally designed by strategy experts and formatted for easy integration into planning, decks, or competitive reviews.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748035604857,"sku":"medirom-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/medirom-bcg-matrix.png?v=1772204051","url":"https:\/\/matrixbcg.com\/products\/medirom-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}